Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If they got some media coverage--you know, interview with a local TV station or newspaper--would they do a PR? These type trade shows always get covered by the local press--and NYC is fine by me for LOCAL news. LOL
It looks like .016 is breakout for SMVI
NWMT chart is, what is the word? UGLY
[chart]www.stockcharts.com/c-sc/sc?s=nwmt&p=D&yr=0&mn=5&dy=0&i=p47853893138&a=175682084&r=3559[/chart
Watch for LGDI before the end of the year....real news with revenue numbers.
Competitive Technologies Announces European Regional Distributor
FAIRFIELD, Conn., Nov. 30, 2009 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that its Geneva, Switzerland-based distributor, Life Episteme SARL, has established a joint venture, Life Episteme Italia srl, with Florence, Italy-based Hospital Consulting SpA, to distribute CTT's pain therapy medical device, Calmare(R) Therapy Treatment throughout Italy.
"Life Episteme is eager to embark on this joint venture with Hospital Consulting, which is well known in the Italian healthcare sector," said Life Episteme co-founder Dr. Domenico Pecorini. "This agreement with Hospital Consulting finalizes the first of several regional joint ventures we have in negotiation as part of our strategy for distributing CTT's innovative Calmare(R) Therapy Treatment in the global marketplace."
"Hospital Consulting has the infrastructure in place, and has extensive experience working with healthcare providers throughout Italy," said John B. Nano, CTT's Chairman, President and CEO. "We're pleased to have them join the distribution team for our Calmare(R) Therapy Treatment, which has already successfully treated more than 3,000 patients in Europe and the U.S.
"Pain treatment is moving to the forefront of medical care, globally. In Italy, Europe's largest university, La Sapienza of Rome, will prominently feature our Calmare(R) Therapy Treatment at its newly-established medical school dedicated to the treatment of pain. Hospital Consulting's recognition of important trends in healthcare confirms our belief that the ability to help patients with debilitating pain by using our non-invasive pain therapy treatment device is an attractive alternative for physicians who may be reluctant to prescribe powerful, addictive narcotics that have been linked to harmful, potentially fatal, adverse side effects.
"Recently, the University of Chicago Medical Center announced that, '... a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.' This makes the rapid introduction of our Calmare(R) Therapy Treatment into the global healthcare marketplace even more compelling. In fact, similar to the Hippocratic Oath, a fundamental principle taught to all medical students is 'Primum Non Nocere,' meaning, 'First, do no harm.'"[/b
The Calmare(R) Therapy Treatment is a prime example of CTT's strategy to connect clinical science to patient care. Developed in Italy by CTT's client, Professor Giuseppe Marineo, the device was brought to CTT through the efforts of the Zangani Investor Community(TM) and with the cooperation of Mr. Guiseppe Belcastro, Legal Counsel for Professor Marineo. The device, with a biophysical rather than a biochemical approach, uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin. CTT has exclusive worldwide rights to the Calmare(R) Therapy Treatment which has U.S. FDA acceptance and Medical Device CE Mark certification from the E.U. allowing sales throughout the U.S., Europe and several other countries. CTT partner, GEOMC Co., Ltd. of Korea, is producing the device commercially for worldwide distribution. Several distribution agreements, including the one with Life Episteme, are in place covering 45 countries around the world, accounting for nearly 55% of the world's population. For more information on the device, visit www.CalmareTT.com.
About Hospital Consulting, SpA
Based in Florence, Italy, Hospital Consulting SpA provides advisory, management and organizational services to the healthcare and environment sectors. Hospital Consulting provides hospitals and other health care providers throughout Italy with valuable training, facility design and development as well as innovative risk assessment and information technology solutions. For more information, see Hospital Consulting's website: www.hospital-consulting.it.
About Life Episteme SARL
The privately held Life Episteme SARL based in Geneva, Switzerland, is a medical device distribution company. The experience of the co-founders, Dr. Domenico Pecorini, Vincenzo de Bustis Figarola, and Paolo Pepe, has provided the group with strong relationships in government, business, and technology spheres in various countries around the world. Visit Dr. Pecorini's website: www.scienceparkrome.eu.
About Life Episteme Italia, srl
This newly formed Joint Venture will benefit from the know-how and contacts of both Hospital Consulting (HC) and Life Episteme SARL group (LEG). The success of the operation will be pursued sharing competencies and dedicating high-profile resources. LEG will bring strong relationships, financial services and internationalization to the partnership. HC will provide decades of presence, success and experience in the market. The President of Life Episteme Italia (LEI) will be Dott.ssa Marisa Giampaoli, Managing Director of Hospital Consulting group, who is well respected at the highest levels of the Italian public and private health sector. Umberto Marangoni, the Country General Manager for Hospital Consulting, will serve as LEI's Managing Director. Before becoming the Country General Manager, he worked many years in the same positions in Italy and abroad, for Ohmeda and Draeger Medical, the world leaders in Anesthesia and Critical Care. LEI and the Italian activities will become fully operational beginning January 1, 2010.
About Zangani Investor Community(TM)
The Zangani Investor Community(TM) was created to facilitate scientific and commercial relationships between American, European and Chinese entities. Visit Zangani's website: www.zangani.com.
About Professor Guiseppe Marineo
Professor Guiseppe Marineo is a researcher and bioengineer, who advanced theories to reformulate the concept of disease and the corresponding treatment from a biophysical rather than a biochemical point of view. He is the founder of Delta R&D, a bioengineering research center with a unique history. Visit Delta R&D's website: www.deltard.com/eng.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
Contact:
IR Services, LLC
Johnnie D. Johnson
860 434 2465
jdjohnson@corpirservices.com
Ahhh--- a sophisticated investor, I see.
Good Luck and Happy Thanksgiving.
You are confusing financiers with institutional investors. No problem--common mistake.
Institutional investors do not INVEST in subpenny stocks--financiers may give them money for free trading stock at market discounts--but financiers are NOT investing in a company's future--nor are they buying in the open market.
Institutions DO NOT buy sub-penny stocks. Nice try.
I bet CTT has news next week. They are way overdue on their PR's--non since Nov. 5--ironically announcing they retained a PUBLIC RELATIONS agency!! LOL
It takes time to get the PR going...but between now and their 10-Q--when we know they will be reporting last quarter with the most revenue they have seen in 2 years---- there will most likely be other news that RF Binder PR will be putting out.
JMO.
But my bet is the news machine starts on Tuesday.
What if morphine is determined to be a bad idea during cancer treatments?--because it encourages cancer growth!! What would that mean to a company like CTT? Doctors would have to consider other alternatives to treat for chronic pain.
Check this out
Morphine May Help Tumors Spread in Cancer Patients
HealthDay
Wed Nov 18, 11:48 pm ET
WEDNESDAY, Nov. 18 (HealthDay News) -- Two new studies add to growing evidence that morphine and other opiate-based painkillers may promote the growth and spread of cancer cells.
The papers, scheduled to be presented Wednesday at an international cancer conference in Boston, also demonstrate how preventing opiates from reaching lung cancer cells reduces cancer cell proliferation, invasion and migration.
The findings from tests with cell cultures and mice suggest that the mu opiate receptor -- where morphine acts in the body -- may offer a potential treatment target.
"If confirmed clinically, this could change how we do surgical anesthesia for our cancer patients. It also suggests potential new applications for this novel class of drugs which should be explored," Patrick A. Singleton, an assistant professor of medicine at the University of Chicago and principal author of both studies, said in a university news release.
Morphine can increase tumor cell proliferation, inhibit the immune system, promote the growth of new blood vessels (angiogenesis) that feed tumors and decrease barrier function. In cancer patients undergoing surgery, decreased barrier function may make it easier for tumors to invade tissue and spread to other parts of the body, while increased angiogenesis helps tumors thrive in a new location.
Singleton and colleagues found that mice without the mu opiate receptor didn't develop tumors when injected with lung cancer cells, while normal mice did develop cancer. The researchers also found that methylnaltrexone -- developed to treat opiate-induced constipation -- reduced the proliferation of cancer cells in normal mice by 90 percent.
About $0.32 per share in cash for LGDI. They have the means to grow without needing a dilutive financing.
Ka Ching! BNXT continues
BNXR chart for stockseekerok
MTIZ, IMDS, MCHL, UTRM
IMDS
UTRM
MCHL
SMTL chart
Low floater...
CTT
Low volume righ tnow--watch for news on FDA approved medical device. Explosion time.
Makes my hair go gray
How about one with only 7 Million in the float?
CTT is on the AMEX and they have a new FDA approved medical device to alleviate chronic pain. Yeah, it is expensive--$2.05. But with that low float, it could run on the medical data at some trials they just completed.
Checked the boards for posts on UTRM-- looks like there are a few more out there on other boards. You can't go up if no one is listening. right?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43582495
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43568672
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43308954
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43579867
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43356507
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43559757
Got PFOB on my screen with a few more that I thinkw ill pop
BLVT, UTRM, to name a few
I guess everyone should have bought and held at $3.00?
I am not saying the company is responsible--I am making a comment that you need to think about influence that traders have on a stock'rise---and fall.
WDAS, IDTA, CYSG, UTRM, IGSM, IWEB, RTGV, VTPI Charts
IDTA
CYSG
UTRM
IGSM
IWEB
RTGV
VTPI
CCRT, MDGC, UTRM, IMDS--followthrough this week
MDGC
UTRM
IMDS
Great charts, icon.
The challenge is to get in before they run--but you get worried that it is too early--and on and on
Watching CTT here for a move like Revlon. On clinical data news
PFOB on watch, stoxx
UTRM is my pick for me, lucy
matt-- your charts are too big--make them smaller and more prople would bother to look. Just a thought.
I have seen some posts on other boards ==actually charts- on UTRM. So yesterday's volue has not gone unnoticed.
UTRM Volume Chart from slojab
BIg volume late in the day
POPN chart
Cornell has a new name, now that everyone knows how bad they are.
It is YA Global Advisors